(NASDAQ: GRFS) Grifols Sa's forecast annual revenue growth rate of 4.46% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Grifols Sa's revenue in 2026 is $8,013,757,777.On average, 17 Wall Street analysts forecast GRFS's revenue for 2026 to be $5,493,563,714,920, with the lowest GRFS revenue forecast at $5,197,227,549,572, and the highest GRFS revenue forecast at $5,835,966,059,104. On average, 14 Wall Street analysts forecast GRFS's revenue for 2027 to be $5,854,530,041,620, with the lowest GRFS revenue forecast at $5,395,930,917,984, and the highest GRFS revenue forecast at $6,383,259,765,872.
In 2028, GRFS is forecast to generate $6,307,628,725,992 in revenue, with the lowest revenue forecast at $5,934,286,410,948 and the highest revenue forecast at $6,738,725,653,308.